A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

A randomized, double-blind, double-dummy, active controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of Cabergoline tablets compared with Bromocriptine mesylate tablets in female patients with hyperprolactinemia

Inclusion criteria

• Women aged 18 to 45 at the time of signing the ICF;
• Clinically diagnosed hyperprolactinemia, with or without pituitary PRL tumor;
• Agree to and abide by the adoption of effective contraceptive measures during the study period (from signing the ICF to 4 weeks after the last administration of the investigational drug);
• voluntarily signed the ICF, could understand and abide by the requirements of this research protocol, and were followed up regularly and on time.

Exclusion criteria

• Women who are pregnant or breastfeeding;
• Those who have previously received carbergoline treatment or radiotherapy, or have a history of allergy to ergol preparations or their derivatives;
• The presence of other types or mixed pituitary tumors；
• hyperprolactinemia syndrome caused by hypothalamic or other intracranial lesions；
• hyperprolactinemia syndrome caused by other systemic diseases;
• Laboratory tests during the screening period meet any of the following conditions:

• aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times ULN, or total bilirubin (TBIL) > 1.5 times ULN, or serum creatinine (Cr) or UREA (UREA)/urea nitrogen (BUN) > 2 times ULN;
• Those who are positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody and Treponema pallidum antibody;
• Hyperprolactinemia: Screening tests show that the PRL recovery rate is less than 40%;
• Those who have received ovulation-inducing agents, drugs that may cause an increase in PRL or other prohibited combination drugs within 4 weeks prior to screening;
• The patients not suitable for participating in this clinical study due to other reasons.